Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b) A multicentric retrospective analysis - Université de Rennes Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2019

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b) A multicentric retrospective analysis

Résumé

Objectives No study has reported clinical results of external-beam radiotherapy specifically for T3b prostate cancer. The possibility of escalating the dose to the involved seminal vesicles (ISV) while respecting the dose constraints in the organs at risk is thus so far not clearly demonstrated. The objective of the study was to analyze the dose distribution and the clinical outcome in a large series of patients who received IMRT for T3b prostate cancer.Materials and methods This retrospective analysis included all patients who received IMRT and androgen deprivation therapy for T3b prostate cancer, between 2008 and 2017, in six French institutions, with available MRI images and dosimetric data.Results A total of 276 T3b patients were included. The median follow-up was 26 months. The median (range) prescribed doses (Gy) to the prostate and to the ISV were 77 (70-80) and 76 (46-80), respectively. The dose constraint recommendations were exceeded in less than 12% of patients for the rectum and the bladder. The 5-year risks of biochemical and clinical recurrences and cancer-specific death were 24.8%, 21.7%, and 10.3%, respectively. The 5year risks of local, pelvic lymph node, and metastatic recurrences were 6.4%, 11.3%, and 15%, respectively. The number of involved lymph nodes (<= 2 or >= 3) on MRI was the only significant prognostic factor in clinical recurrence (HR 9.86) and death (HR 2.78). Grade. 2 acute and 5-year late toxicity rates were 13.2% and 12% for digestive toxicity, and 34% and 31.5% for urinary toxicity, respectively. The dose to the pelvic lymph node and the age were predictive of late digestive toxicity.Conclusion IMRT for T3b prostate cancer allows delivery of a curative dose in the ISV, with a moderate digestive toxicity but a higher urinary toxicity. Lymph node involvement increases the risk of recurrence and death.
Fichier principal
Vignette du fichier
journal.pone.0210514.pdf (1.55 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-02049134 , version 1 (04-09-2019)

Identifiants

Citer

Flora Goupy, Stephane Supiot, David Pasquier, Igor Latorzeff, Ulrike Schick, et al.. Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b) A multicentric retrospective analysis. PLoS ONE, 2019, 14 (1), pp.e0210514. ⟨10.1371/journal.pone.0210514⟩. ⟨hal-02049134⟩
203 Consultations
106 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More